Information For the User
Prazosin (2.5mg) Sustained Release Tablets

Prazyle XL 2.5 Tablet

Prazyle XL 2.5 Tablet

Composition:
Each sustained-release tablet contains:
• Prazosin I.P. 2.5 mg
• Excipients q.s.
• Colour: Approved colour used

Dosage Form:
Sustained Release Tablet

Therapeutic Category:
Alpha-1 Adrenergic Receptor Antagonist – Antihypertensive Agent

Description:

Prazyle XL 2.5 Tablet is a long-acting formulation of Prazosin, a selective alpha-1 adrenergic receptor blocker. It reduces vascular resistance and promotes smooth muscle relaxation in the arterioles and veins, resulting in a decrease in blood pressure. The sustained-release formulation ensures prolonged antihypertensive effect, improving patient compliance and minimizing fluctuations in blood pressure. It is used for the management of hypertension and in conditions where relief of urinary outflow obstruction is desired.

Indications:

• Essential hypertension
• Management of symptoms of benign prostatic hyperplasia (BPH)
• Adjunct therapy in congestive heart failure when indicated

Mechanism of Action:

Prazosin selectively blocks postsynaptic alpha-1 adrenergic receptors, leading to relaxation of vascular smooth muscle, reduction in systemic vascular resistance, and decreased blood pressure. By reducing urethral resistance, it also improves urine flow in patients with BPH. The sustained-release form allows gradual release of Prazosin over time, maintaining stable plasma levels and consistent therapeutic effect.

Dosage and Administration:

• Recommended starting dose: 2.5 mg once daily, preferably at bedtime
• Dose may be titrated based on blood pressure response
• Can be taken with or without food
• Follow the physician’s instructions for optimal blood pressure control

Contraindications:

• Hypersensitivity to Prazosin or any excipients
• History of orthostatic hypotension or syncope related to alpha-blockers

Warnings and Precautions:

• Caution in patients with severe coronary artery disease
• Monitor for postural hypotension, especially with the first dose
• Use with caution in patients with renal or hepatic impairment
• Not recommended for use in children

Drug Interactions:

• Additive hypotensive effects may occur with other antihypertensives
• Concomitant use with PDE5 inhibitors may increase the risk of symptomatic hypotension
• NSAIDs may reduce the antihypertensive effect

Adverse Effects:

• Common: Dizziness, headache, fatigue, palpitations, postural hypotension
• Rare: Syncope, priapism, nasal congestion, nausea

Overdose:

• Symptoms: Severe hypotension, dizziness, syncope
• Treatment: Supportive care including IV fluids and vasopressors if needed
• Close monitoring of blood pressure and cardiac status is recommended

Storage:

Store below 30°C in a dry, cool place
Protect from light and moisture
Keep out of reach of children

Manufactured in India for:

Cafoli™
LIFECARE

Cafoli Lifecare Pvt. Ltd.
(An ISO 9001: 2015 Certified Co.)
Plot no.: 367-FF, Industrial Area Phase-I,
Panchkula-134113
TM: Trademark Applied for